February 10, 2025

Summary: NLS Pharmaceutics and Kadimastem plan to merge to develop multi-target therapies for diabetes-associated neurological and sleep disorders, leveraging NLS’s DOXA platform—integrating orexin signaling, neuroprotection, and metabolic regulation—as a potential disease-modifying treatment beyond glucose control. Key Takeaways: Research underscores the connection between diabetes, neurodegeneration, and sleep disorders, collectively termed diabetes-associated neurological and sleep disorders Unlike…

Prompted by Philips’ exit from the diagnostics business, Natus launches an MPR PG HST rental program. Since Philips announced its exit from sleep diagnostics about a year ago, former Philips home sleep testing (HST) customers have contacted Natus to request a similar HST rental offering to the program Philips previously ran. Natus, which only offered…